secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2025-06-13T23:59:59+00:00
Accession:  0000320017-25-000037
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata Therapeutics raises CEO salary to $717,229, CMO salary to $599,342 in amended employment agreements
--------------------------------------------------------------------------------

- CEO David Mazzo base salary increased to $717,229 from $633,032; $12,000 non-accountable expense allowance removed.
- CMO Kristen Buck base salary increased to $599,342 from $550,000.
- Amended severance terms for CEO, CMO, CAO Nisco, and GC Imam; includes COBRA reimbursement changes and Section 409A clarifications.
- Change in Control definition amended to include shareholder-approved complete liquidation, subject to 409A requirements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001725000037/0000320017-25-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001725000037/clbs-20250610.htm
  HTML page:      https://secwatch.observer/filing/0000320017-25-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer